Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial.

Authors :: Wierzbowska A
Wawrzyniak E
Pluta A
Robak T
Mazur GJ
Dmoszynska A
Cermak J
Oriol A
Lysak D
Arthur C
Doyle M
Xiu L
Ravandi F
Kantarjian HM
Source :: American journal of hematology [Am J Hematol] 2018 May; Vol. 93 (5), pp. E125-E127. Date of Electronic Publication: 2018 Feb 24.
Publication Year :: 2018

Subjects :: Aged
Aged, 80 and over
Decitabine therapeutic use
Humans
Leukemia, Myeloid, Acute genetics
Leukemia, Myeloid, Acute mortality
Survival Analysis
Decitabine pharmacology
Karyotyping
Leukemia, Myeloid, Acute drug therapy
Monosomy
Progression-Free Survival

Full Text Access

Tools